## 3 Results and Discussion
The obtained results show that the Weibull model was superior over the other tested models, as it translates the complex release behavior of tRES from nanoparticles. The lipid composition of the formulation is of utmost relevance in the design of the tRES release kinetics from SLN, because the lipid is responsible for the loading of drug in the matrix. We have demonstrated that stearic acid figuring in both formulations (F1.RES and F2.RES) promotes the slow rate of drug release from the developed SLN. However, during the release experiments, the drug is being dissolved, thereby increasing the matrix porosity, which promotes a faster drug release. Research has demonstrated that raising the amount of stearic acid associated with the hydrophilic polymer promotes matrix solubilization increases the matrix porosity and promotes a faster drug \begin{table}
\begin{tabular}{c c c} \hline \hline \multirow{2}{*}{**Mathematical Models**} & \multicolumn{2}{c}{**Regression Coefficient (R2)**} \\ \cline{2-3}  & **F1.RES** & **F2.RES** \\ \hline Korsmeyer-Peppas & 0.9680 & 0.9752 \\ Higuchi & 0.8469 & 0.8734 \\ First Order & 0.9757 & 0.9814 \\ Weibull & 0.9916 & 0.9939 \\ Zero Order & 0.9700 & 0.9683 \\ \hline \hline \end{tabular}
\end{table} 
Table 4: Regression coefficient obtained after adjusted the drug release data of tRES-loaded SLN with five mathematical models. Figure 4: Trans-resveratrol (tRES) release profile from SLN after 24 h of analysis (n = 6). F1.RES comprised 5.0% SA, 3.5% P407, 0.18% MP, 0.02% PP, and 0.1% tRES, and F2.RES comprised 5.0% SA, 1.2% SPC, 3.5% P407, 0.18% MP, 0.02% PP, and 0.1% tRES. release [60]. Due to the lipophilic character of SLN, these particles act as absorption enhancers upon oral administration, contributing to improving the bioavailability of the loaded active ingredients [61; 62; 63; 64]. SLN also show great potential for the oral delivery of nutraceuticals [47; 65; 66; 67], which is a research area that is receiving growing attention both from academia and industry [68; 69; 70; 71]. Nutraceuticals bridge the gap from conventional pharmacological therapy, and the use of natural substances able to prevent/delay the onset of long-term pathological conditions. They are placed in a gray area between pharmaceuticals and food, and have been recently named as: \"the phytocomplex, if they derive from a food of vegetal origin, and as the pool of the secondary metabolites if they derive from a food of animal origin, concentrated and administered in the more suitable pharmaceutical form\" [14; 68]. This study addresses the emerging new branch of \"Nanonutraceutical Science\" [67; 72]. Nanonutraceutical formulations are being exploited for their efficacy, safety, and effect, and could be another tool in the arsenal of strategies that are helpful in managing health conditions, especially in patients who are not eligible for a conventional pharmacological therapy. Recent examples are the end points reached on the use of milk thistle (_Sillybum marianum_) in liver diseases, and the use of the apple phytocomplex against hypercholesterolemiaemy [9; 73]. The stability of nutraceuticals in new nanoformulations is a recent research area with foreseen important outcomes. SLN can be further processed in foodstuffs to increase their ratio in active ingredients. Together with the chemical protection that SLN may offer, the modified release profile of resveratrol can also be exploited for other administration routes to reduce cytotoxicity, improve cell-stress response, offer photoproduction, and increase drug solubility and antitumor response.